Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DE-089 in dry eye disease
NCT03216096Phase 1Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Sep 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of diquafosol in dry eye disease (DED), sponsored by Santen Pharmaceutical. Primary endpoint: Corneal fluorescein staining score at Week 4. Started Sep 2017; status: completed.
02
Drugs
diquafosol
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT03216096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03216096.